The human immune system is a constant sentinel that seeks out unwelcome invaders in the body such as viruses, bacteria, as well as some elements that might be an indication of disease or dysfunction. Cancer and precancer cells are considered as foreign bodies and are cleared by the immune system. However, in most cases cancerous cells evade the surveillance of the immune system and proliferate into a malignancy. It has been observed that the offending tumor cells undergo molecular mechanisms to escape discovery or to locally tamp down the immune system’s normal response. This discovery prompted researchers to  begin testing cancer therapies that not only attack the tumor cells directly, as is the case with radio- and chemotherapies, but also give the immune system a boost by preventing immune system suppression. Immuno oncology assays are aimed at monitoring the interaction between cancer cells and host immune cells. 

The global immuno oncology assays market can be segmented based on technology, assay, and region. Based on technology, the immuno oncology assays market can be classified into PCR, immunoassay, flow cytometry, next-generation sequencing, and other. In terms assay, the immuno oncology assays market can be categorized into cell proliferation assays, cell migration & invasion assays, phagocytosis assays, immune cell killing assays, and other. Based on region, the global immuno oncology assays market can be segmented into North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. 

The immune oncology assays market is expected to expand at a significant growth rate during the forecast period. Factors such as rise in the incidence of cancer, technological advancements in molecular techniques, extensive research and development in cancer diagnostics, and ongoing clinical trials in cancer immunotherapy are expected to accelerate the immuno oncology assays market. According to the World Health Organization (WHO), cancer accounted for 8.8 million deaths in 2015.  Worldwide, one out of six deaths is due to cancer. Hence, an increase in the prevalence of cancer and rise in the need for personalized medicine are expected to drive the immune oncology assays market during the forecast period. With the introduction of highly sensitive molecular techniques such as next generation sequencing (NGS) and digital PCR (dPCR), researchers and clinicians can analyze various circulating biomarkers. These innovative technologies provide a comparatively less expensive and less invasive way for diagnosis, prognosis, and therapy selection in patients throughout their treatment plan.                   

North America and Europe are expected to be prominent regions of the immuno oncology assays market. Well-established health care infrastructure and funding from public and private sectors for research and development are projected to fuel the immuno oncology assays market in these regions. Acceptance of technologically advanced devices and ongoing clinical trials in cancer therapy are anticipated to drive the market in North America. According to the American Cancer Society, an estimated 1,735,350 new cancer cases will be diagnosed and 609,640 cancer deaths will occur in the U.S. in 2018. Asia Pacific is expected to account for a significant share of the global immuno oncology assays market, in terms of revenue, during the forecast period. Rise in support from governing bodies and the private sector in developing effective and novel therapeutics in the field of cancer is anticipated to drive the market in the region. Moreover, high prevalence of cancer in Asia Pacific is likely to offer significant opportunities to players operating in the immuno oncology assays market. Japan and Australia are well-established regions of the market in Asia Pacific. However, emerging economies such as China and India are expected to provide significant opportunities to the immuno oncology assays market in the region. Other regions such as Middle East & Africa and Latin America are anticipated to offer expansion opportunities to the immuno oncology assays market in the near future, due to an increase in government support for cancer research and rapidly developing health care industry in the regions. 

Major players operating in the global Immuno oncology assays market include Agilent Technologies, Inc, Thermo Fisher Scientific, Inc., Cisbio, Illumina, Inc., PerkinElmer, Inc., Crown Bioscience Inc., InSphero. Merck & Company, Inc., F. Hoffmann-La Roche Ltd. and HTG Molecular Diagnostics, Inc.

This study by TMR is all-encompassing framework of the dynamics of the market. It mainly comprises critical assessment of consumers' or customers' journeys, current and emerging avenues, and strategic framework to enable CXOs take effective decisions.

Our key underpinning is the 4-Quadrant Framework EIRS that offers detailed visualization of four elements:

  • Customer Experience Maps
  • Insights and Tools based on data-driven research
  • Actionable Results to meet all the business priorities
  • Strategic Frameworks to boost the growth journey

The study strives to evaluate the current and future growth prospects, untapped avenues, factors shaping their revenue potential, and demand and consumption patterns in the global market by breaking it into region-wise assessment.

The following regional segments are covered comprehensively:

  • North America
  • Asia Pacific
  • Europe
  • Latin America
  • The Middle East and Africa

The EIRS quadrant framework in the report sums up our wide spectrum of data-driven research and advisory for CXOs to help them make better decisions for their businesses and stay as leaders.

Below is a snapshot of these quadrants.

1. Customer Experience Map

The study offers an in-depth assessment of various customers’ journeys pertinent to the market and its segments. It offers various customer impressions about the products and service use. The analysis takes a closer look at their pain points and fears across various customer touchpoints. The consultation and business intelligence solutions will help interested stakeholders, including CXOs, define customer experience maps tailored to their needs. This will help them aim at boosting customer engagement with their brands.

2. Insights and Tools

The various insights in the study are based on elaborate cycles of primary and secondary research the analysts engage with during the course of research. The analysts and expert advisors at TMR adopt industry-wide, quantitative customer insights tools and market projection methodologies to arrive at results, which makes them reliable. The study not just offers estimations and projections, but also an uncluttered evaluation of these figures on the market dynamics. These insights merge data-driven research framework with qualitative consultations for business owners, CXOs, policy makers, and investors. The insights will also help their customers overcome their fears.

3. Actionable Results

The findings presented in this study by TMR are an indispensable guide for meeting all business priorities, including mission-critical ones. The results when implemented have shown tangible benefits to business stakeholders and industry entities to boost their performance. The results are tailored to fit the individual strategic framework. The study also illustrates some of the recent case studies on solving various problems by companies they faced in their consolidation journey.

4. Strategic Frameworks

The study equips businesses and anyone interested in the market to frame broad strategic frameworks. This has become more important than ever, given the current uncertainty due to COVID-19. The study deliberates on consultations to overcome various such past disruptions and foresees new ones to boost the preparedness. The frameworks help businesses plan their strategic alignments for recovery from such disruptive trends. Further, analysts at TMR helps you break down the complex scenario and bring resiliency in uncertain times.

The report sheds light on various aspects and answers pertinent questions on the market. Some of the important ones are:

1. What can be the best investment choices for venturing into new product and service lines?

2. What value propositions should businesses aim at while making new research and development funding?

3. Which regulations will be most helpful for stakeholders to boost their supply chain network?

4. Which regions might see the demand maturing in certain segments in near future?

5. What are the some of the best cost optimization strategies with vendors that some well-entrenched players have gained success with?

6. Which are the key perspectives that the C-suite are leveraging to move businesses to new growth trajectory?

7. Which government regulations might challenge the status of key regional markets?

8. How will the emerging political and economic scenario affect opportunities in key growth areas?

9. What are some of the value-grab opportunities in various segments?

10. What will be the barrier to entry for new players in the market?

Note: Although care has been taken to maintain the highest levels of accuracy in TMR’s reports, recent market/vendor-specific changes may take time to reflect in the analysis.

Custom Market Research Services

TMR offers custom market research services that help clients to get information on their business scenario required where syndicated solutions are not enough.

REQUEST CUSTOMIZATION

Immuno Oncology Assays Market

Pre Book